Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump ahead in next-generation therapies across several of its established focus areas and a couple of new ones.

Boehringer Ingelheim GmbH announced three deals in July, two of which aim to build on its success in fibrosis, which kicked off in 2014 when FDA approved its idiopathic pulmonary fibrosis (IPF) drug Ofev nintedanib, making it one of the first two products marketed for the indication...